ApoE2 and Alzheimer′s disease: time to take a closer look
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is the most common form of dementia among the elderly. It currently affects approximately 5.1 million Americans, a number predicted to triple by 2050. AD is clinically manifested as progressive loss of memory and cognitive function, and is characterized pathologically by the formation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFT). Since its discovery in 1906, extensive research has been undertaken to define AD pathogenesis and to develop treatments; however, the cause of AD remains largely unknown and no therapeutic success has been achieved in over 200 AD drug trials conducted in the past decade (Cummings et al., 2014). These challenges underscore the need for increased research focus to better understand AD risk mechanisms that would allow for the development of strategies aimed at AD prevention and early intervention. Human apolipoprotein E (ApoE) is a 299-amino-acid protein with a molecular mass of 36 kDa. In the periphery, ApoE is primarily present in the liver, kidney, and spleen, where it plays a critical role in cholesterol and lipid transport and metabolism. In the central nervous system, ApoE is synthesized and secreted by astrocytes, microglia, and, to a lesser extent, neurons. Brain ApoE is involved in injury repair via the redistribution of lipids among neurons and the modulation of neurite outgrowth and cerebrovascular integrity. Human ApoE exists as three major isoforms, ApoE2, ApoE3 and ApoE4, which are the products of three alleles at a single gene locus on the long arm of chromosome 19. These isoforms differ structurally by two amino acid substitutions at residues 112 and 158: ApoE2 (Cys112, Cys158), ApoE3 (Cys112, Arg158), and ApoE4 (Arg112, Arg158) (Figure 1). ApoE consists of two functional domains joined by a flexible hinge region: an amino-terminal domain that contains a highly positively charged receptor-binding region composed mainly of arginine and lysine residues; and a carboxyl-terminal domain which includes a lipid-binding region (Figure 1). Substitutions of two amino acid residues in the three ApoE isoforms significantly alter their receptor-binding and lipid-binding affinities (Mahley and Rall, 2000). ApoE2 has a much lower binding affinity for low-density lipoprotein (LDL) receptors compared to ApoE3 and ApoE4. Furthermore, ApoE2 and ApoE3 preferentially bind to small, phospholipid-enriched high-density lipoproteins (HDL) whereas ApoE4 preferentially binds to larger, triglyceride-enriched lipoproteins. It has been postulated that the unique domain interaction between the residue Arg61 and Glu255 might underlie the detrimental effects of ApoE4 in the brain (Figure 1).Figure 1: The schematic representation of the structural and functional domains of human apolipoprotein E (ApoE) isoforms.Human ApoE gene is composed of four exons interrupted by three introns (pattern box: coding region; open box: untranslated region). The ApoE2, ApoE3 and ApoE4 isoforms are coded by ε2, ε3 and ε4 alleles of the ApoE gene, respectively. The isoforms differ from each other in two amino acid substitutions at residues 112 and 158 resulting from C→T or T→C point mutation in exon 4 as indicated. ApoE contains two functional domains: the N-terminal domain containing the receptor-binding region (residues 134–150) and the C-terminal domain containing the lipid-binding region (residues 244–272). The unique domain interaction between Arg61 and Glu255 in ApoE4 might underlie its detrimental effects in the brain.Human ApoE isoforms have been shown to confer differential susceptibility to AD. As the most common isoform, ApoE3 is present in approximately 75% of the population and is believed to play a neutral role in AD. ApoE2 is relatively rare, with only 5% incidence, and is considered to be a protective variant against AD. By contrast, as the most potent genetic risk factor for AD, ApoE4 exists in only about 20% of the population; however, it is present in nearly 50% of AD patients. It is estimated that individuals who carry two ApoE2 alleles or one ApoE2 allele and one ApoE3 allele are 40% less likely to develop AD than those who carry two ApoE3 alleles; whereas, people who have one ApoE4 allele and one ApoE3 allele or two ApoE4 alleles are 3.2 or 14.9 times more likely to develop AD than those carrying two ApoE3 alleles. While an immense amount of work has been done to examine the role of ApoE in AD pathogenesis, most studies have focused on identifying AD risk mechanisms conferred by ApoE4 through comparisons between ApoE4 and ApoE3 and between ApoE4 carriers and noncarriers. Clinically, ApoE4 has been associated with the accelerated rate and severity of cognitive decline, with a lower age of onset, and with altered response to AD treatments. On the molecular level, ApoE4-expressing brains have been demonstrated to be less efficient in Aβ clearance; this might be a consequence of reduced ApoE protein quantity and reduced affinity of ApoE for Aβ binding, resulting
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 3×
“In addition, ApoE4 brains have been associated with greater brain atrophy, decreased cerebral glucose metabolism, impaired synaptic function, and defective hippocampal neurogenesis (Liu et al., 2013).”
BackgroundInfluentialAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“Since its discovery in 1906, extensive research has been undertaken to define AD pathogenesis and to develop treatments; however, the cause of AD remains largely unknown and no therapeutic success has been achieved in over 200 AD drug trials conducted in the past decade (Cummings et al., 2014).”
BackgroundSex modifies the APOE ‐related risk of developing Alzheimer disease
Altmann, A., Tian, L., Henderson, V. W., Greicius, M. D., & Alzheimer's Disease Neuroimaging Initiative Investigators (2014) · Annals of Neurology · doi:10.1002/ana.24135 · Cited by 891 · cited 1×
“A significant interaction between ApoE2 and sex was also revealed in these analyses, in which a protective role of ApoE2 was detected in male but not female subjects (Altmann et al., 2014).”
Nagy, Z. S., Esiri, M. M., Jobst, K. A., Johnston, C., Litchfield, S., Sim, E., & Smith, A. D. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00331-c · Cited by 250
APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old
Berlau, D. J., Corrada, M. M., Head, E., & Kawas, C. H. (2009) · Neurology · doi:10.1212/01.wnl.0000343853.00346.a4 · Cited by 185 · cited 2×
“In addition, ApoE2-expressing AD brains appear to express less NFT formation (Morris et al., 1995), although other studies demonstrate the opposite outcome (Berlau et al., 2009).”
ResultHippocampal atrophy rates and CSF biomarkers in elderly APOE 2 normal subjects
Chiang, G. C., Insel, P. S., Tosun, D., Schuff, N., Truran-Sacrey, D., Raptentsetsang, S. T., Jack, C. R., Aisen, P. S., Petersen, R. C., Weiner, M. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ffe4d1 · Cited by 94 · cited 1×
“Since its discovery in 1906, extensive research has been undertaken to define AD pathogenesis and to develop treatments; however, the cause of AD remains largely unknown and no therapeutic success has been achieved in over 200 AD drug trials conducted in the past decade (Cummings et al., 2014).”
BackgroundMorris, C. M., Benjamin, R., Leake, A., McArthur, F. K., Candy, J. M., Ince, P. G., Torvik, A., Bjertness, E., & Edwardson, J. A. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(94)12126-b · Cited by 38 · cited 2×
“In addition, ApoE2-expressing AD brains appear to express less NFT formation (Morris et al., 1995), although other studies demonstrate the opposite outcome (Berlau et al.”
Result
Cited by
Fernandez, C. G., Hamby, M. E., McReynolds, M. L., & Ray, W. J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00014 · Cited by 277
“In the context of AD, APOE2 has been relatively understudied, although some research is ongoing (Wu and Zhao, 2016).”
BackgroundLipid and Lipoprotein Metabolism in Microglia
Loving, B. A., & Bruce, K. D. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00393 · Cited by 255
“Each isoform differs by 2 amino acid substitutions (ApoE2 [Cys112, Cys158], ApoE3 [Cys112, Arg158], and ApoE4 [Arg112, Arg158]), which significantly alters their lipid and receptor binding affinities (Mahley and Rall, 2000; Wu and Zhao, 2016).”
BackgroundInfluentialWu, L., Zhang, X., & Zhao, L. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.2262-17.2018 · Cited by 185
“Gene delivery of ApoE2 markedly reduced brain amyloid pathology in an AD mouse model (Zhao et al., 2016).”
BackgroundSelf-citationProtective genes and pathways in Alzheimer’s disease: moving towards precision interventions
Seto, M., Weiner, R. L., Dumitrescu, L., & Hohman, T. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00452-5 · Cited by 135
“Carrying two APOE-ε4 alleles can increase risk by up to 15-fold [71, 72].”
BackgroundGlycolytic Metabolism, Brain Resilience, and Alzheimer’s Disease
Zhang, X., Alshakhshir, N., & Zhao, L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.662242 · Cited by 134
Self-citation
Metadata
- Authors
- Zhao, L., & Wu, L.
- Venue
- Neural Regeneration Research
- Publisher
- Medknow
- Published
- 2016
- Volume
- 11
- Issue
- 3
- Pages
- 412
- ISSN
- 1673-5374 (ISSN-L)
- OpenAlex
- W2316885128
- Cited by
- 69
- References
- 7
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ApoE2 and Alzheimer′s disease: time to take a closer look. https://app.cochat.ai/papers/10.4103/1673-5374.179044
- The paper
- Zhao, L., & Wu, L. (2016). ApoE2 and Alzheimer′s disease: time to take a closer look. Neural Regeneration Research. https://doi.org/10.4103/1673-5374.179044
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.